Citations

Clear

9383 citation(s) found for "Thomas, PS".

Systemic Neutrophil Gelatinase-Associated Lipocalin Alterations in Chronic Pancreatitis: A Multicenter, Cross-Sectional Study
Torok, Molly, Pfau, Timothy, Mace, Thomas A. , Cole, Rachel M. , Hart, Phil A. , Krishna, Somashekar G. , Lara, Luis F. , Ramsey, Mitchell L. , Fogel, Evan L. , Forsmark, Chris E. , Li, Liang , Park, Walter G. , Vege, Santhi Swaroop , Yadav, Dhiraj , Conwell, Darwin L. , Cruz‐Monserrate, Zobeida , Krishna, Somashekar G , Gumpper, Kristyn , Chasser, Kaylin M. , Pita-Grisanti, Valentina , Belury, Martha Ann , Culp, Stacey , Fisher, William P. , Pandol, Stephen J. , Serrano, José , Van Den Eeden, Stephen K

Mayo Clinic

Clinical and Translational Gastroenterology | January 29, 2024 | Volume: 15 | Issue: 4 | Pages: e00686

10.14309/ctg.0000000000000686 | PMID 38284831 Get It

INTRODUCTION: Chronic pancreatitis (CP) is a progressive fibroinflammatory disorder lacking therapies and biomarkers. Neutrophil gelatinase-associated lipocalin (NGAL) is a proinflammatory cytokine elevated during inflammation that binds fatty acids (FAs) such as linoleic acid. We hypothesized that systemic NGAL could serve as a biomarker for CP and, with FAs, provide insights into inflammatory and metabolic alterations. METHODS: NGAL was measured by immunoassay, and FA composition was measured by gas chromatography in plasma (n = 171) from a multicenter study, including controls (n = 50), acute and recurrent acute pancreatitis (AP/RAP) (n = 71), and CP (n = 50). Peripheral blood mononuclear cells (PBMCs) from controls (n = 16), AP/RAP (n = 17), and CP (n = 15) were measured by cytometry by time-of-flight. RESULTS: Plasma NGAL was elevated in subjects with CP compared with controls (area under the curve [AUC] = 0.777) or AP/RAP (AUC = 0.754) in univariate and multivariate analyses with sex, age, body mass index, and smoking (control AUC = 0.874; AP/RAP AUC = 0.819). NGAL was elevated in CP and diabetes compared with CP without diabetes ( P < 0.001). NGAL + PBMC populations distinguished CP from controls (AUC = 0.950) or AP/RAP (AUC = 0.941). Linoleic acid was lower, whereas dihomo-γ-linolenic and adrenic acids were elevated in CP ( P < 0.05). Linoleic acid was elevated in CP with diabetes compared with CP subjects without diabetes ( P = 0.0471). DISCUSSION: Elevated plasma NGAL and differences in NGAL + PBMCs indicate an immune response shift that may serve as biomarkers of CP. The potential interaction of FAs and NGAL levels provide insights into the metabolic pathophysiology and improve diagnostic classification of CP.
Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper
Perucca, Emilio , French, Jacqueline A. , Aljandeel, Ghaieb , Balestrini, Simona , Braga, Patrícia , Burneo, Jorge G. , Charway‐Felli, Augustina , Cross, J. Helen , Galanopoulou, Aristea S. , Jain, Satish , Jiang, Yuwu , Kälviäinen, Reetta , Lim, Shih Hui , Meador, Kimford J. , Mogal, Zarine , Nabbout, Rima , Sofia, Francesca , Triki, Chahnez , Walker, Matthew C. , Wiebe, Samuel , Wilmshurst, Jo M. , Yacubian, Elza Márcia Targas , Kapur, Jaideep , Felli, Augustina Charway , Somerville, Ernest , Sperling, Michael R , Triki, Chahnez , Trinka, Eugen , Walker, Matthew C , Wiebe, Samuel , Wilmshurst, Jo M , Wirrell, Elaine C , Yacubian, Elza Márcia , Kapur, Jaideep , Galanopoulou, Aristea , Cross, Helen J , Perucca, Emilio , French, Jacqueline , Balestrini, Simona , Meador, Kimford J , Burneo, Jorge G , Jain, Satish , Somerville, Ernest , Sperling, Michael R. , Trinka, Eugen , Wirrell, Elaine

Mayo Clinic

Epilepsia | January 27, 2024 | Volume: 65 | Issue: 3 | Pages: 533-541

10.1111/epi.17877 | PMID 38279786 Get It

Abstract A variety of terms, such as “antiepileptic,” “anticonvulsant,” and “antiseizure” have been historically applied to medications for the treatment of seizure disorders. Terminology is important because using terms that do not accurately reflect the action of specific treatments may result in a misunderstanding of their effects and inappropriate use. The present International League Against Epilepsy (ILAE) position paper used a Delphi approach to develop recommendations on English‐language terminology applicable to pharmacological agents currently approved for treating seizure disorders. There was consensus that these medications should be collectively named “antiseizure medications”. This term accurately reflects their primarily symptomatic effect against seizures and reduces the possibility of health care practitioners, patients, or caregivers having undue expectations or an incorrect understanding of the real action of these medications. The term “antiseizure” to describe these agents does not exclude the possibility of beneficial effects on the course of the disease and comorbidities that result from the downstream effects of seizures, whenever these beneficial effects can be explained solely by the suppression of seizure activity. It is acknowledged that other treatments, mostly under development, can exert direct favorable actions on the underlying disease or its progression, by having “antiepileptogenic” or “disease‐modifying” effects. A more‐refined terminology to describe precisely these actions needs to be developed.
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
Bantilan, Kurt S. , Smith, Alexandra N., Maurer, Matthew J. , Teruya‐Feldstein, Julie , Matasar, Matthew J. , Moskowitz, Alison J. , Straus, David J. , Noy, Ariela , Palomba, M. Lia , Horwitz, Steven M. , Portlock, Carol S., Nowakowski, Grzegorz S. , Moskowitz, Craig H. , Hamlin, Paul A , Cerhan, James R , Salles, Gilles A , Nowakowski, Grzegorz S , Zelenetz, Andrew D , Maurer, Matthew , Horwitz, Steven M , Matasar, Matthew , Noy, Ariela , Cerhan, James R. , Habermann, Thomas M. , Salles, Gilles , Zelenetz, Andrew D.

Mayo Clinic

Blood Advances | January 25, 2024 | Volume: 8 | Issue: 9 | Pages: 2172-2181

10.1182/bloodadvances.2023011408 | PMID 38271621 Get It

Abstract Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered the standard-of-care for patients with advanced-stage diffuse large B-cell lymphoma (DLBCL), despite findings that patients with nongerminal center B-cell like (non-GCB) have significantly worse outcome with this regimen. We evaluated the prognostic significance of baseline risk factors, including cell of origin (COO) classified by the Hans algorithm, within an alternative chemoimmunotherapy program. At Memorial Sloan Kettering Cancer Center (MSK), 151 patients with DLBCL received sequential R-CHOP induction and (R)-ICE (rituximab, ifosfamide, carboplatin, and etoposide) consolidation. Outcome analysis based on COO was validated with a propensity score–matched cohort treated with R-CHOP from the Mayo Clinic component of the Molecular Epidemiology Resource (MER). Among the patients with GCB (n = 69) and non-GCB (n = 69) at MSK, event-free survival (EFS) of non-GCB was superior to that of GCB (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.29-0.98). Overall survival (OS) demonstrated an association in the same direction but was not statistically significant (HR, 0.68; 95% CI, 0.33-1.42). Propensity score–matched patients from MSK (n = 108) demonstrated a small attenuation in the HRs for EFS (HR, 0.57; 95% CI, 0.27-1.18) and OS (HR, 0.76; 95% CI, 0.33-1.79) and were no longer statistically significant. In contrast, the matched MER cohort (n = 108) demonstrated an EFS association (HR, 1.17; 95% CI, 0.70-1.95) and OS association (HR, 1.13; 95% CI, 0.64-2.00) in the opposite direction, but were also not statistically significant. R-CHOP induction and (R)-ICE consolidation may overcome the negative prognostic impact of the non-GCB phenotype, per the Hans algorithm, and can be preferentially selected for this population. This trial was registered at www.ClinicalTrials.gov as #NCT00039195 and #NCT00712582.
Management of Bone Loss in Revision Total Knee Arthroplasty: An International Consensus Symposium
Flevas, Dimitrios A. , Jerabek, Seth A. , Bostrom, Mathias P. , Haddad, Fares S. , Fehring, Thomas K. , Berry, Daniel J. , Bornes, Troy D. , Marcos, Carolena Rojas , Wright, Timothy M. , Sculco, Thomas P. , Flevas, Dimitrios A , Rojas Marcos, Carolena E , Berry, Daniel J , Sculco, Peter K. , Jiranek, William A. , Valle, Alejandro González Della , Brenneis, Marco

Mayo Clinic

HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery | January 25, 2024 | Volume: 20 | Issue: 2 | Pages: 141-181

10.1177/15563316231202750 | PMID 39281983 Get It

The evaluation, classification, and treatment of significant bone loss after total knee arthroplasty (TKA) continue to be a complex and debated topic in revision TKA (rTKA). Despite the introduction of new evidence and innovative technologies aimed at addressing the approach and care of severe bone loss in rTKA, there is no single document that systematically incorporates these newer surgical approaches. Therefore, a comprehensive review of the treatment of severe bone loss in rTKA is necessary. The Stavros Niarchos Foundation Complex Joint Reconstruction Center Hospital for Special Surgery, dedicated to clinical care and research primarily in revision hip and knee replacement, convened a Management of Bone Loss in Revision TKA symposium on June 24, 2022. At this meeting, the 42 international invited experts were divided into groups; each group was assigned to discuss questions related to 1 of the 4 topics: (1) assessing preoperative workup and imaging, anticipated bone loss, classification system, and implant surveillance; (2) achieving durable fixation in the setting of significant bone loss in revision TKA; (3) managing patellar bone loss and the extensor mechanism in cases of severe bone loss; and (4) considering the use of complex modular replacement systems: hinges, distal femoral, and proximal tibial replacements. Each group came to consensus, when possible, based on an extensive literature review and interactive discussion on their group topic. This document reviews each these 4 areas, the consensus of each group, and directions for future research.
The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis
Salim, Hamza , Saifi, Motaz , Ruzieh, Mohammed , Azar, Jehad , Nazzal, Zaher , Salim, Hamza , Musmar, Basel , Ayyad, Mohammed

Mayo Clinic

Current Cardiology Reviews | January 24, 2024 | Volume: 20 | Issue: 2 | Pages: No page available

10.2174/011573403x283174240110025442 | PMID 38265377 Get It

Background: Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide. Polypills, containing various combinations of medications for primary and secondary CVD prevention, have been developed to enhance medication adherence and reduce the healthcare burden of CVD. However, their effectiveness compared to usual care remains uncertain. Objective: This meta-analysis aimed to evaluate the effects of polypills on cardiovascular risk factors, major adverse cardiovascular events (MACE), and medication adherence. Methods: We conducted a comprehensive search for large-scale randomized controlled trials and observational studies comparing the effects of polypills versus usual care on CVD risk factors and events. Outcomes included changes in systolic and diastolic blood pressure (SBP, DBP), lipid profiles, occurrence of MACE, and medication adherence. Results: The use of polypills led to a statistically significant yet clinically modest reduction in SBP (mean difference -1.47 mmHg, 95% CI: -2.50 - -0.44, p<0.01) and DBP (mean difference1.10 mmHg, 95% CI: -1.68 - -0.51, p< 0.01) compared to usual care. Polypills also showed a significant reduction in the risk of MACE (RR: 0.86, 95% CI: 0.77 -0.95, p<0.01). There was a non-significant reduction in LDL and HDL levels. Adherence to medication improved by up to 17% in polypill users compared to those on usual care (p < 0.01). A multivariable metaregression analysis suggested that adherence may be the underlying factor responsible for the observed effect of the polypills on blood pressure. Conclusion: Polypills were found to significantly reduce SBP, DBP and MACE. An improvement in medication adherence was also observed among polypill users, which might be responsible for the significant reduction in SBP observed users. Future research might benefit from exploring a more personalized approach to the composition of polypills, which could reveal a more clinically significant impact of increased adherence on CVD outcomes.
Lewy body dementia: Overcoming barriers and identifying solutions
Agarwal, Kanishka, Backler, Wendi, Bloom, Leah, Cha, Jang‐Ho , Denslow, Maria, Ferman, Tanis J. , Gomperts, Stephen N. , Irizarry, Michael C. , Kantarci, Kejal , Kaushik, Harsh, Kietlinski, Matt, Koenig, Aaron, Leverenz, James B., McLean, Pamela J. , Montine, Thomas J. , Moose, Sandra O., Panier, Valery, Ringel, Michael S. , Scholz, Sonja W. , Small, J C, Ward, Rebecca , Witten, L.M., Ward, Rebecca A , Scholz, Sonja W , Kantarci, Kejal , Ferman, Tanis J , McLean, Pamela J , Bayram, Ece , Boeve, Bradley F. , Galasko, Douglas , Galvin, James E. , Leverenz, James B. , McKeith, Ian G. , O'Brien, John Tiernan , Ramanathan, Sharad , Small, Jonnell, Sperling, Reisa Anne , Taylor, Angela E. , Taylor, John‐Paul , Hyman, Bradley T.

Mayo Clinic

Alzheimer's & Dementia | January 24, 2024 | Volume: 20 | Issue: 3 | Pages: 2298-2308

10.1002/alz.13674 | PMID 38265159 Get It

AbstractDespite its high prevalence among dementias, Lewy body dementia (LBD) remains poorly understood with a limited, albeit growing, evidence base. The public‐health burden that LBD imposes is worsened by overlapping pathologies, which contribute to misdiagnosis, and lack of treatments. For this report, we gathered and analyzed public‐domain information on advocacy, funding, research outputs, and the therapeutic pipeline to identify gaps in each of these key elements. To further understand the current gaps, we also conducted interviews with leading experts in regulatory/governmental agencies, LBD advocacy, academic research, and biopharmaceutical research, as well as with funding sources. We identified wide gaps across the entire landscape, the most critical being in research. Many of the experts participated in a workshop to discuss the prioritization of research areas with a view to accelerating therapeutic development and improving patient care. This white paper outlines the opportunities for bridging the major LBD gaps and creates the framework for collaboration in that endeavor.Highlights A group representing academia, government, industry, and consulting expertise was convened to discuss current progress in Dementia with Lewy Body care and research. Consideration of expert opinion,natural language processing of the literature as well as publicly available data bases, and Delphi inspired discussion led to a proposed consensus document of priorities for the field.
Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102
Saber, Wael , Bansal, Aasthaa , Li, Li , Scott, Bart L. , Sangaralingham, Lindsey R. , Thao, Viengneesee , Roth, Joshua A. , Wright, Winona , Pidala, Joseph A. , Mishra, Asmita , Westervelt, Peter, Nakamura, Ryotaro , Ramsey, Scott D. , Li, Lily , Mishra, Asmita , Maziarz, Richard Thomas , McGuirk, Joseph , Cutler, Corey S. , Ramsey, Scott , Steuten, Lotte , McGuirk, Joseph P.

Mayo Clinic

JCO Oncology Practice | January 23, 2024 | Volume: 20 | Issue: 4 | Pages: 572-580

10.1200/op.23.00413 | PMID 38261970 Get It

PURPOSE BMT CTN 1102 was a phase III trial comparing reduced-intensity allogeneic hematopoietic cell transplantation (RIC alloHCT) to standard of care for persons with intermediate- or high-risk myelodysplastic syndrome (MDS). We report results of a cost-effectiveness analysis conducted alongside the clinical trial. METHODS Three hundred eighty-four patients received HCT (n = 260) or standard of care (n = 124) according to availability of a human leukocyte antigen–matched donor. Cost-effectiveness was calculated from US commercial and Medicare perspectives over a 20-year time horizon. Health care utilization and costs were estimated using propensity score–matched cohorts of HCT recipients in the OptumLabs Data Warehouse (age 50-64 years) and Medicare (age 65 years and older). EuroQol 5 Dimension (EQ-5D) surveys of trial participants were used to derive health state utilities. RESULTS Extrapolated 20-year overall survival for those age 50-64 years was 29% for HCT (n = 105) versus 13% for usual care (n = 44) and 31% for HCT (n = 155) versus 12% for non-HCT (n = 80) for those age 65 years and older. HCT was more effective (+2.36 quality-adjusted life-years [QALYs] for age 50-64 years and +2.92 QALYs for age 65 years and older) and more costly (+$452,242 in US dollars (USD) for age 50-64 years and +$233,214 USD for age 65 years and older) than usual care, with incremental cost-effectiveness ratios of $191,487 (USD)/QALY and $79,834 (USD)/QALY, respectively. For persons age 50-64 years, there was a 29% chance that HCT was cost-effective using a willingness-to-pay (WTP) threshold of $150K (USD)/QALY and 51% at a $200K (USD)/QALY. For persons age 65 years and older, the probability was 100% at a WTP >$150K (USD)/QALY. CONCLUSION Among patients age 65 years and older with high-risk MDS, RIC HCT is a high-value strategy. For those age 50-64 years, HCT is a lower-value strategy but has similar cost-effectiveness to other therapies commonly used in oncology.
Alliance A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur).
Gholami, Sepideh , White, Sarah B. , Goulet, Christopher C., Jee, Kyung‐Wook , Wright, Chadwick , Yaeger, Rona , Shergill, Ardaman , Hong, Theodore S. , Meyerhardt, Jeffrey A. , Meyerhardt, Jeffrey A , Hitchcock, Kathryn E. , Romesser, Paul B. , Shi, Qian , Dixon, Jesse G. , Wu, Christina , George, Thomas J. , O’Reilly, Eileen M. , Miller, Eric D.

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: TPS236-TPS236

10.1200/jco.2024.42.3_suppl.tps236 Get It

TPS236 Background: For patients with oligometastatic colorectal cancer (CRC), aggressive local therapy of isolated metastases, particularly in the liver, has been associated with long-term progression-free survival and overall survival (OS) primarily based on retrospective evidence. However, in patients with limited metastatic CRC that is deemed inoperable or those with additional disease outside of the liver or lungs, the role of local ablative therapies, including microwave ablation (MWA) and stereotactic body radiation therapy (SBRT), to render patients disease free is less clear. Further, despite the long history of treating oligometastatic CRC with local therapy, which is provider biased and not evidence based, questions remain regarding the benefit of extending the paradigm of metastatic directed therapy to patients with more extensive disease. This trial seeks to use a pragmatic multimodality approach that mirrors the current clinical dilemma. This study is designed to evaluate the safety and efficacy of adding total ablative therapy (TAT) of all sites of disease to standard of care systemic treatment in those with limited metastatic CRC. Methods: A022101 is a National Clinical Trials Network randomized phase III study planned to enroll 364 patients with newly diagnosed metastatic CRC (BRAF wild-type, microsatellite stable) with ≤4 sites of metastatic disease on baseline imaging. Liver-only metastatic disease is not permitted, and lesions must be amenable to any combination of surgical resection, MWA, and/or SBRT with SBRT required for at least one lesion. Patients receive first-line systemic therapy for 4-6 months and are then randomized 1:1, stratified by number of metastatic organ sites (1-2 vs. 3-4), timing of metastatic disease diagnosis (de novo vs. secondary), and presence of metastatic disease outside the liver and lungs in at least one site. Patients in Arm 1 will receive TAT which consists of treatment of all metastatic sites with SBRT ± MWA ± surgical resection followed by standard of care systemic therapy. Patients in Arm 2 will continue with standard of care systemic therapy alone. The primary endpoint is OS. Secondary endpoints include event-free survival, treatment-related toxicities, and local recurrence with exploratory biomarker analyses. The study needs 346 evaluable patients combined in the 2 arms to demonstrate an improvement in OS with a hazard ratio of 0.7 to provide 80% power with a one-sided alpha of 5%. The trial utilizes a group sequential design with two interim analyses (25% and 50% of events) for futility. The trial activated in January 2023 and recruitment is ongoing. Support: U10CA180821, U10CA180882; https://acknowledgments.alliancefound.org. U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG). Clinical trial information: NCT05673148 .
Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort.
Emiloju, Oluwadunni Eunice, Yin, Jun , Koubek, Emily J. , Lou, Yanyan , Seetharam, ­Mahesh , Edelman, Martin Joseph, Jiang, Yixing , Posey, James , Davis, S. Lindsey , Roberts, Lewis R. , Takebe, Naoko , Hendrickson, Andrea E. Wahner , Costello, Brian A. , Roberts, Lewis R , Reid, Joel M. , Borad, Mitesh J. , Edelman, Martin J. , Kaseb, Ahmed O , Gores, Gregory J. , Kaufmann, Scott H. , Hubbard, Joleen M.

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: 507-507

10.1200/jco.2024.42.3_suppl.507 Get It

507 Background: Navitoclax (ABT-263) is an oral Bcl-2 homology-3 mimetic that binds with high affinity to pro-survival Bcl-2 proteins, resulting in apoptosis. Sorafenib, an oral multi kinase inhibitor inhibits tumor angiogenesis and also promotes apoptosis. The efficacy of either agent alone is limited; however, preclinical studies demonstrate synergy with the combination of navitoclax and sorafenib. Methods: In this phase 1 pharmacokinetic and pharmacodynamic study (NCT01364051), we evaluated the combination of navitoclax and sorafenib in a dose escalation cohort of patients with refractory solid tumors, with an expansion cohort in hepatocellular carcinoma (HCC). The study agents were provided by the Cancer Therapy Evaluation Program at National Cancer Institute under CRADA. Navitoclax and sorafenib were administered continuously on days 1 through 21 of 21-day cycles. The maximum tolerated dose (MTD) was determined using the continual reassessment method. Results: Ten patients were enrolled in the dose escalation cohort and 15 patients with HCC were enrolled in the expansion cohort. Two dose levels were tested, dose level 1 (navitoclax 150 mg daily plus sorafenib 400 mg twice daily) and dose level 2 (navitoclax 200 mg daily plus sorafenib 400 mg twice daily). At dose level 1, one dose limiting toxicity (DLT) [grade 3 aspartate aminotransferase elevation] was observed among 6 patients treated at this dose level. In a cohort of 3 patients treated at dose level 2, two DLTs were observed (grade 3 hypertension, and grade 3 rash), hence dose level 1 was identified as the MTD. Among all patients, the most common grade 3 toxicity was thrombocytopenia (5 patients, 20%): there were no grade 4 or 5 toxicities (Table). Patients received a median of 2 cycles (range 1-36 cycles) and all patients were off study treatment at data cut off. Six patients in the expansion cohort had stable disease, 5 had progressive disease and 4 with unavailable data. There were no partial or complete responses. Drug-drug interaction between navitoclax and sorafenib was not observed. The combination of navitoclax and sorafenib did not increase induction of apoptosis compared with navitoclax alone. Conclusions: Navitoclax plus sorafenib resulted in manageable, but not ideal toxicities for continuous oral administration which precluded dose escalation. The lack of clinical benefit in the HCC expansion cohort does not support further development of this combination for the treatment of advanced HCC. Clinical trial information: NCT01364051 . [Table: see text]
Development of an improved risk stratification scheme for stage II and III colorectal cancers through incorporation of the digital pathology biomarker QuantCRC.
Pai, Rish K. , Hartley, Christopher , Sonbol, Bassam Bassam, Patel, Bhavik N. , Shivji, Sameer , Conner, James , Swallow, Carol J. , Savage, Paul D. , Cyr, David P. , Kirsch, Richard , Pai, Reetesh K. , Wu, Christina , Kosiorek, Heidi , Banerjee, Imon , Hagen, Catherine E. , Hartley, Christopher P , Graham, Rondell P. , Bekaii‐Saab, Tanios , Xie, Hao , Sinicrope, Frank A. , Westerling-Bui, Thomas

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: 162-162

10.1200/jco.2024.42.3_suppl.162 Get It

162 Background: There is a need to improve current risk stratification of stage II and III colorectal cancer (CRC) to better inform risk of recurrence and guide adjuvant chemotherapy. The purpose of this study is to examine whether integration of QuantCRC, an AI-based digital pathology biomarker utilizing hematoxylin and eosin-stained slides, provides improved risk stratification over current American Society of Clinical Oncology (ASCO) guidelines. Methods: ASCO and QuantCRC-integrated risk schemes were applied to an observational cohort of 1,068 stage II and III CRCs. The stage II integrated scheme utilizes pT3 vs. pT4 and QuantCRC-derived risk groups. The stage III integrated scheme utilizes pT1-3 vs. pT4, pN1 vs. pN2, and QuantCRC-derived risk groups. Performance metrics included log-rank test, hazard ratios and Somers’ Dxy rank correlation. Results: Integration of QuantCRC provides improved risk stratification compared to the ASCO scheme for stage II and III CRC. The QuantCRC-integrated scheme placed more stage II tumors in the low-risk group compared to the ASCO scheme (69.3% vs. 60.4%) without decreased 3-year RFS. The QuantCRC-integrated scheme provided larger hazard ratios (HR) for both intermediate-risk (3.04, 95%CI 1.81-5.10, P=2.8x10-5) and high-risk (4.62, 95%CI 2.02-10.61, P=0.0003) groups compared to ASCO intermediate-risk (2.09, 95%CI 1.21-3.63, P=0.008) and high-risk (3.08, 95%CI 1.57-6.01, P=0.001) groups. The QuantCRC-integrated scheme for stage III tumors identified a small group of 80/518 (15.4%) CRCs at very high risk of recurrence with HR of 4.08 (95%CI 2.68-6.23, P=6.5x10-11) compared to a HR of 2.42 (95%CI 1.72-3.38, P=3.1x10-7) for 228/518 (44.0%) high-risk CRCs in the ASCO scheme. QuantCRC-integrated risk groups remained prognostic in stage III CRCs when stratified by presence or absence of any adjuvant chemotherapy. No difference in RFS were seen in QuantCRC-integrated low-risk and intermediate-risk stage III CRCs stratified by 3 vs. 6-months of oxaliplatin-based adjuvant chemotherapy suggesting that these two groups can be treated with 3-months of adjuvant therapy. Conclusions: Incorporation of QuantCRC into risk stratification provides a powerful predictor of RFS that has potential to guide subsequent treatment and surveillance.